Clinical trial NCT01859312: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Official title: A Pilot Study Assessing the Use of Continuous Subcutaneous Hydrocortisone Infusion in the Treatment of Congenital Adrenal Hyperplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Adrenal Insufficiency
Excess Androgen
Congenital Adrenal Hyperplasia (CAH)
Keywords: Glucocorticoids
Adrenal Insufficiency
Congenital Adrenal Hyperplasia (CAH)
Adrenal
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
Collaborators: name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted: 2013-05-21
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Background:

* Congenital adrenal hyperplasia (CAH) is a genetic disorder of the adrenal gland. The adrenal gland is located in the abdomen and produces small amounts of hormones such as cortisol, aldosterone, and androgen. These hormones help control blood pressure, protect the body, and maintain good health, especially during development. People with CAH do not make enough cortisol and aldosterone, and make too much androgen. This can lead to serious medical problems. The standard treatment is to take pills that mimic the effects of cortisol and aldosterone. However, treatment with pills can have long-term side effects because of the higher doses needed, and may not work well for some people.
* A possible new treatment for CAH is to use a pump to deliver cortisol under the skin. Similar pumps are often used to give insulin to people with diabetes. Researchers think that a cortisol pump might be able to help the body use the cortisol more effectively than taking pills. They want to compare the results of a cortisol pump and standard pill treatments for CAH.

Objectives:

- To compare the effectiveness of a cortisol pump with standard cortisol pill therapy for CAH.

Eligibility:

- Men and women at least 18 years of age who have CAH (see more details in Eligibility section below).

Design:

* This study will involve four inpatient hospital stays at the National Institutes of Health in Bethesda, MD over 6 months (spaced 2 months apart). The first and last stays will last about 5 days. The second and third stays will last about 3 days.
* Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
* At the first study visit, participants will provide regular blood and urine samples. They will also have imaging studies. These studies will look at the bones, fat, and muscles in the abdomen and pelvis.
* Participants will receive a cortisol pump during the first visit. They will be shown how to use the pump. They will also learn what to do, if they need to take extra "stress dose" cortisol pills.
* At the second and third visits, the cortisol dose given with the pump will be adjusted as needed. Blood and urine samples will also be collected. No imaging studies are scheduled for these visits.
* The last study visit will have the same tests as the first visit. Participants will be offered the chance to continue with the pump treatment for 1 more year, or go back to their standard pill treatment.

Study type: Interventional non-randomized trial

Official title: A Pilot Study Assessing the use of Continuous Subcutaneous Hydrocortisone Infusion In the Treatment of Congenital Adrenal Hyperplasia

Estimated enrollment: 8

Study Start Date: May 2013

Estimated Study Completion Date: December 2016

Sponsoring Institute: National Institute of Child Health and Human Development

\<TAB\>ELIGIBILITY

Inclusion criteria

1. Men and women 18 years of age or older with classic congenital adrenal hyperplasia (21-Hydroxylase deficiency)
2. High adrenal androgens in the blood, and
3. One or more of the following conditions: obesity, fatty liver, risk for diabetes, low bone mass, inability to tolerate cortisol pills

Exclusion criteria

1. Pregnancy
2. Breast feeding
3. Use of inhaled or oral steroids for diseases other than CAH
4. Use of estrogen-containing birth control pills
5. Use of medicines that cross-react with hydrocortisone
6. Use of stress dose steroids for illness during the last 30 days prior to joining the study

Detailed description: Congenital adrenal hyperplasia (CAH) is a common genetic endocrine disorder, with 21-hydroxylase enzyme deficiency accounting for 95% of the cases. 21-hydroxylase deficiency presents with a spectrum of clinical manifestations ranging from salt-wasting and virilization of female neonates (classic CAH) to symptomatic (precocious puberty, short stature, acne) or asymptomatic hyperandrogenemia (non-classic CAH). Classic CAH is characterized by impaired cortisol and mineralocorticoid biosynthesis, which triggers adrenocorticotropic hormone (ACTH) hyper-secretion and accumulation of adrenal androgens. Glucocorticoid treatment of patients with classic CAH focuses on cortisol replacement and prevention of the ACTH-driven androgen excess. Current conventional glucocorticoid treatment regimens (short or long-acting agents dosed once, twice or thrice daily) have failed to simulate physiological cortisol secretion and suppress adrenal androgen overproduction, without supraphysiologic replacement. Short-term overtreatment with glucocorticoids can lead to iatrogenic Cushing syndrome and long-term use has been associated with the development of obesity, visceral adiposity, insulin resistance and osteoporosis. Isolated case reports have provided evidence that continuous subcutaneous hydrocortisone infusion (CSHI) can mimic physiologic cortisol release and lead to improved CAH control at doses similar to or lower than the traditional treatment. This pilot study aims to test the hypothesis that difficult-to-treat adult patients with classic CAH will have better adrenal androgen control and improved CAH and glucocorticoid-related comorbidities, when they receive near-physiologic cortisol replacement therapy via CSHI compared to conventional glucocorticoid treatment. In addition, this study will provide information on the safety and tolerability of CSHI, and will generate data that will be used in the design of future pediatric studies.

Eligibility criteria: * INCLUSION CRITERIA:
* Patients with known classic CAH due to 21-hydroxylase deficiency as evidenced by hormonal and genetic testing
* Male or female patients 18 years or older
* Females must have a negative pregnancy test initially and at all visits. Sexually active females must be using a medically acceptable method of contraception.
* Patients with elevated adrenal androgens (defined as 17-OHP \>1200 ng/dL and androstenedione \>210 ng/dL)
* One or more co-morbidities:\<TAB\>
* Obesity \[body mass index (BMI) greater than 30.0 kg/m(2)\]
* Fatty liver disease; assessed by AST/ALT liver enzyme ratio (AST to ALT ratio \<1 (11)) liver ultrasound or MRI imaging (Steatosis score as previously described)
* Low insulin sensitivity; assessed by the Homeostasis Model Assessment Insulin Resistance (HOMA-IR) method \[HOMA-IR = insulin (micro U/ml) times glucose (mmol/L)/ 22.5\]. Elevated HOMA-IR index is defined as \>2.6 in adults17.
* Osteopenia \[bone mineral density by DEXA (at the spine, hip, or forearm) with T-score of -1 to -2.5) or osteoporosis (bone mineral density by DEXA (at the spine, hip, or forearm) with T-score of \<-2.5\] defined according to World Health Organization (WHO).
* Glucocorticoid-related gastrointestinal side effects (nausea, vomiting, dyspepsia, anorexia, gastritis, peptic ulcer disease and gastric bleeding)

EXCLUSION CRITERIA:

* Co-morbid conditions requiring daily administration of medications that induce hepatic enzymes or interfere with the metabolism of glucocorticoids
* Females who are pregnant or lactating
* Patients on inhaled or oral steroids given for reasons other than treatment of CAH
* Women who have taken estrogen-containing oral contraceptive pills within 6 weeks of recruitment
* Patients who required stress dose glucocorticoids for an illness within 4 weeks of recruitment
* Patients who changed their glucocorticoid agent within 3 months of recruitment
* Patients who underwent bilateral adrenalectomy
* Co-morbid conditions that could interfere with the ability to comply to the protocol

Primary outcomes:
measure: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700
timeFrame: At baseline
measure: Number of Patients With 17-OH Progesterone Levels Equal or Below 1,200 ng/dL at 0700
timeFrame: At 6 months
Secondary outcomes:
measure: Participants Mean Level of 17-OHP at 0700
timeFrame: At baseline
measure: Participants Mean Level of 17-OHP at 0700
timeFrame: At 6 months
measure: Participants Mean Level of 17-OHP Area Under the Curve (AUC) - 24 Hours
timeFrame: At baseline
measure: Participants Mean Level of 17-OHP Area Under the Curve (AUC) - 24 Hours
timeFrame: At 6 months
measure: Participants Mean Level of 17-OHP Area Under the Curve (AUC) - Daytime (0700-1500)
timeFrame: At baseline
measure: Participants Mean Level of 17-OHP Area Under the Curve (AUC) - Daytime (0700-1500)
timeFrame: At 6 months
measure: Participants Mean Level of 17-OHP Area Under the Curve (AUC) - Midday (1500 - 2300)
timeFrame: At baseline
measure: Participants Mean Level of 17-OHP Area Under the Curve (AUC) - Midday (1500 - 2300)
timeFrame: At 6 months
measure: Participants Mean Level of 17-OHP Area Under the Curve (AUC) - Nighttime (2300 - 0700)
timeFrame: At baseline
measure: Participants Mean Level of 17-OHP Area Under the Curve (AUC) - Nighttime (2300 - 0700)
timeFrame: At 6 months
measure: Participants Mean Level of Androstenedione at 0700
timeFrame: At baseline
measure: Participants Mean Level of Androstenedione at 0700
timeFrame: At 6 months
measure: Participants Mean Level of Androstenedione Area Under the Curve (AUC) - 24 Hours
timeFrame: At baseline
measure: Participants Mean Level of Androstenedione Area Under the Curve (AUC) - 24 Hours
timeFrame: At 6 months
measure: Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Daytime (0700-1500)
timeFrame: At baseline
measure: Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Daytime (0700-1500)
timeFrame: At 6 months
measure: Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Midday (1500 - 2300)
timeFrame: At baseline
measure: Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Midday (1500 - 2300)
timeFrame: At 6 months
measure: Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Nighttime (2300 - 0700)
timeFrame: At baseline
measure: Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Nighttime (2300 - 0700)
timeFrame: At 6 months
measure: Participants Mean Level of ACTH at 0700
timeFrame: At baseline
measure: Participants Mean Level of ACTH at 0700
timeFrame: At 6 months
measure: Participants Mean Level of ACTH Area Under the Curve (AUC) - 24 Hours
timeFrame: At baseline
measure: Participants Mean Level of ACTH Area Under the Curve (AUC) - 24 Hours
timeFrame: At 6 months
measure: Participants Mean Level of ACTH Area Under the Curve (AUC) - Daytime (0700-1500)
timeFrame: At baseline
measure: Participants Mean Level of ACTH Area Under the Curve (AUC) - Daytime (0700-1500)
timeFrame: At 6 months
measure: Participants Mean Level of ACTH Area Under the Curve (AUC) - Midday (1500 - 2300)
timeFrame: At baseline
measure: Participants Mean Level of ACTH Area Under the Curve (AUC) - Midday (1500 - 2300)
timeFrame: At 6 months
measure: Participants Mean Level of ACTH Area Under the Curve (AUC) - Nighttime (2300 - 0700)
timeFrame: At baseline
measure: Participants Mean Level of ACTH Area Under the Curve (AUC) - Nighttime (2300 - 0700)
timeFrame: At 6 months
measure: Participants Mean Progesterone Levels at 0700
timeFrame: At baseline
measure: Participants Mean Progesterone Level at 0700
timeFrame: At 6 months
measure: Participants Mean Level of Progesterone Area Under the Curve (AUC) - 24 Hours
timeFrame: At baseline
measure: Participants Mean Level of Progesterone Area Under the Curve (AUC) - 24 Hours
timeFrame: At 6 months
measure: Participants Mean Level of Progesterone Area Under the Curve (AUC) - Daytime (0700-1500)
timeFrame: At baseline
measure: Participants Mean Level of Progesterone Area Under the Curve (AUC) - Daytime (0700-1500)
timeFrame: At 6 months
measure: Participants Mean Level of Progesterone Area Under the Curve (AUC) - Midday (1500 - 2300)
timeFrame: At baseline
measure: Participants Mean Level of Progesterone Area Under the Curve (AUC) - Midday (1500 - 2300)
timeFrame: At 6 months
measure: Participants Mean Level of Progesterone Area Under the Curve (AUC) - Nighttime (2300 - 0700)
timeFrame: At baseline
measure: Participants Mean Level of Progesterone Area Under the Curve (AUC) - Nighttime (2300 - 0700)
timeFrame: At 6 months
measure: Participant Lean Body Mass
timeFrame: At baseline
measure: Participant Lean Body Mass
timeFrame: At 6 months
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: National Institutes of Health Clinical Center, 9000 Rockville Pike
state: Maryland
Study officials:
affiliation: National Institutes of Health Clinical Center (CC)
name: Deborah P Merke, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab. 2009 May;94(5):1548-54. doi: 10.1210/jc.2008-2380. Epub 2009 Feb 17.
citation: Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, Reynolds JC, Hanna RM, Merke DP. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2012 Dec;97(12):4429-38. doi: 10.1210/jc.2012-2102. Epub 2012 Sep 18.
citation: Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, Han TS, Carroll PV, Conway GS, Rees DA, Stimson RH, Walker BR, Connell JM, Ross RJ; United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab. 2010 Nov;95(11):5110-21. doi: 10.1210/jc.2010-0917. Epub 2010 Aug 18.
citation: Nella AA, Mallappa A, Perritt AF, Gounden V, Kumar P, Sinaii N, Daley LA, Ling A, Liu CY, Soldin SJ, Merke DP. A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2016 Dec;101(12):4690-4698. doi: 10.1210/jc.2016-1916. Epub 2016 Sep 28.
citation: Mallappa A, Nella AA, Sinaii N, Rao H, Gounden V, Perritt AF, Kumar P, Ling A, Liu CY, Soldin SJ, Merke DP. Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2018 Oct;89(4):399-407. doi: 10.1111/cen.13813. Epub 2018 Aug 8.